173 related articles for article (PubMed ID: 23039249)
1. Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab.
Perrier C; Arijs I; Staelens D; Breynaert C; Cleynen I; Covens K; Ferrante M; Van Assche G; Vermeire S; de Hertogh G; Schuit F; Rutgeerts P; Ceuppens JL
Immunology; 2013 Jan; 138(1):47-56. PubMed ID: 23039249
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
[TBL] [Abstract][Full Text] [Related]
4. Profile of soluble cytokine receptors in Crohn's disease.
Gustot T; Lemmers A; Louis E; Nicaise C; Quertinmont E; Belaiche J; Roland S; Van Gossum A; Devière J; Franchimont D
Gut; 2005 Apr; 54(4):488-95. PubMed ID: 15753533
[TBL] [Abstract][Full Text] [Related]
5. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
[TBL] [Abstract][Full Text] [Related]
6. High expression of the "A Disintegrin And Metalloprotease" 19 (ADAM19), a sheddase for TNF-α in the mucosa of patients with inflammatory bowel diseases.
Franzè E; Caruso R; Stolfi C; Sarra M; Cupi ML; Ascolani M; Sedda S; Antenucci C; Ruffa A; Caprioli F; MacDonald TT; Pallone F; Monteleone G
Inflamm Bowel Dis; 2013 Mar; 19(3):501-11. PubMed ID: 23429442
[TBL] [Abstract][Full Text] [Related]
7. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.
Olsen T; Cui G; Goll R; Husebekk A; Florholmen J
Scand J Gastroenterol; 2009; 44(6):727-35. PubMed ID: 19294580
[TBL] [Abstract][Full Text] [Related]
8. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
[TBL] [Abstract][Full Text] [Related]
9. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
11. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
[TBL] [Abstract][Full Text] [Related]
12. Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease.
Nishiwaki T; Ina K; Goto H; Watanabe O; Tsuzuki T; Furuta R; Ando T; Hibi K; Kusugami K
J Gastroenterol; 2005 Feb; 40(2):128-36. PubMed ID: 15770395
[TBL] [Abstract][Full Text] [Related]
13. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
14. Serum bacterial toxins are related to the progression of inflammatory bowel disease.
Qiu H; Sun X; Sun M; He C; Li Z; Liu Z
Scand J Gastroenterol; 2014 Jul; 49(7):826-33. PubMed ID: 24853095
[TBL] [Abstract][Full Text] [Related]
15. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
Raddatz D; Bockemühl M; Ramadori G
Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
Arijs I; Quintens R; Van Lommel L; Van Steen K; De Hertogh G; Lemaire K; Schraenen A; Perrier C; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
Inflamm Bowel Dis; 2010 Dec; 16(12):2090-8. PubMed ID: 20848504
[TBL] [Abstract][Full Text] [Related]
17. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
[TBL] [Abstract][Full Text] [Related]
18. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
[TBL] [Abstract][Full Text] [Related]
19. Infliximab inhibits activation and effector functions of peripheral blood T cells in vitro from patients with clinically active ulcerative colitis.
Dahlén R; Strid H; Lundgren A; Isaksson S; Raghavan S; Magnusson MK; Simrén M; Sjövall H; Öhman L
Scand J Immunol; 2013 Sep; 78(3):275-84. PubMed ID: 23713660
[TBL] [Abstract][Full Text] [Related]
20. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
